Treatment Choices for Hepatitis C in Patients with Kidney Disease.
作者信息
Fabrizi Fabrizio, Messa Piergiorgio
机构信息
Division of Nephrology, Maggiore Hospital, IRCCS Foundation, Milano, Italy; and.
School of Medicine, University of Milano, Milano, Italy.
出版信息
Clin J Am Soc Nephrol. 2018 May 7;13(5):793-795. doi: 10.2215/CJN.12621117. Epub 2018 Mar 9.
Abstract
摘要
相似文献
1
Treatment Choices for Hepatitis C in Patients with Kidney Disease.
Clin J Am Soc Nephrol. 2018 May 7;13(5):793-795. doi: 10.2215/CJN.12621117. Epub 2018 Mar 9.
2
Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
Liver Int. 2017 Jul;37(7):974-981. doi: 10.1111/liv.13336. Epub 2017 Jan 2.
3
Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.
Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1615-1623. doi: 10.2215/CJN.02510317. Epub 2017 Sep 7.
4
Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Nefrologia (Engl Ed). 2020 Jan-Feb;40(1):46-52. doi: 10.1016/j.nefro.2019.03.013. Epub 2019 Jun 19.
5
Sofosbuvir in HCV patients with chronic kidney disease: No time for caution.
Liver Int. 2021 Apr;41(4):646-648. doi: 10.1111/liv.14845.
6
Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
Exp Clin Transplant. 2017 Feb;15(Suppl 1):63-67. doi: 10.6002/ect.mesot2016.O50.
7
EASL Recommendations on Treatment of Hepatitis C 2016.
J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22.
8
Hepatitis C and Treatment in Patients with Chronic Kidney Disease.
Dis Mon. 2021 Feb;67(2):101017. doi: 10.1016/j.disamonth.2020.101017. Epub 2020 Jun 16.
9
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
Int J Artif Organs. 2018 Jul;41(7):363-370. doi: 10.1177/0391398818763478. Epub 2018 Mar 27.
10
Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis.
Nephrology (Carlton). 2017 Jul;22(7):562-565. doi: 10.1111/nep.13011.
引用本文的文献
1
[Sustained virologic response in patients with hepatitis C and chronic kidney disease].
Rev Med Inst Mex Seguro Soc. 2022 May 2;60(3):283-288.
2
Direct-acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-term Prospective Observational Study.
Transplant Direct. 2019 Nov 18;5(12):e510. doi: 10.1097/TXD.0000000000000954. eCollection 2019 Dec.
3
Hepatitis C in Hemodialysis Units: diagnosis and therapeutic approach.
J Bras Nefrol. 2019 Oct-Dec;41(4):539-549. doi: 10.1590/2175-8239-JBN-2018-0177.
4
HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents.
Front Med (Lausanne). 2019 Feb 8;6:20. doi: 10.3389/fmed.2019.00020. eCollection 2019.
Zotero 插件